Home › Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors
 

Keywords :   


Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors

2015-04-01 07:33:48| drugdiscoveryonline Home Page

Baxter International Inc. recently announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors

Tags: with results iii positive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »